新光药业(300519) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥70,001,422.20, representing a 4.36% increase year-over-year[3] - Net profit attributable to shareholders decreased by 39.11% to ¥12,274,690.46 in Q3 2024[3] - The net profit after deducting non-recurring gains and losses was ¥11,979,179.22, down 38.86% compared to the same period last year[3] - Net profit for Q3 2024 was CNY 37,782,359.75, down from CNY 58,699,769.38 in the same period last year, reflecting a decrease of 35.6%[17] - The total comprehensive income for the period attributable to the parent company was CNY 37,798,974.14, a decrease from CNY 59,129,468.24 in the previous period[18] - Basic and diluted earnings per share for the period were both CNY 0.24, down from CNY 0.37 in the previous period[18] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥892,451,704.76, a decrease of 4.08% from the end of the previous year[3] - Total assets decreased to CNY 892,451,704.76 from CNY 930,405,790.36, a reduction of 4.1%[16] - Total liabilities decreased to CNY 74,531,962.43 from CNY 86,285,022.17, a decline of 13.5%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥35,382,757.18, down 15.25% year-over-year[3] - Cash received from operating activities decreased by 60.24% to ¥5,841,377.75 compared to ¥14,690,256.67 in the same period last year, primarily due to reduced bank deposit interest[8] - Cash flow from operating activities generated a net amount of CNY 35,382,757.18, compared to CNY 41,748,650.66 in the previous period[20] - Cash inflow from operating activities totaled CNY 212,613,452.57, down from CNY 232,562,979.50 in the previous period[20] - Cash outflow from operating activities was CNY 177,230,695.39, compared to CNY 190,814,328.84 in the previous period[20] - The net cash flow from investing activities turned negative at -¥90,716,421.32 compared to a positive ¥20,486,792.61 in the same period last year, primarily due to increased purchases of financial products[8] - The net cash flow from investing activities was -CNY 90,716,421.32, a significant decrease from CNY 20,486,792.61 in the previous period[20] - The ending balance of cash and cash equivalents was CNY 424,612,128.76, down from CNY 604,265,223.53 at the end of the previous period[21] Investments and Financial Assets - The company reported a significant increase in trading financial assets, rising by 58.06% to ¥245,000,000.00 due to increased investment in financial products[6] - The company’s trading financial assets increased to ¥245,000,000.00 from ¥155,000,000.00 at the beginning of the period[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,112[9] - Major shareholder Wang Yuejun holds 38.25% of the shares, amounting to 61,200,000 shares[9] Operating Costs and Expenses - Total operating costs increased to CNY 177,847,718.97 from CNY 151,115,999.35, marking a rise of 17.8% year-over-year[16] - Research and development expenses were CNY 9,618,279.84, down from CNY 11,763,165.15, a decrease of 18.3%[17] Accounts Receivable and Payable - Accounts receivable increased by 70.28% to ¥17,009,136.33, attributed to higher shipments compared to the previous year[6] - Accounts receivable decreased to CNY 17,009,136.33 from CNY 9,988,937.91, indicating a significant increase of 70.3%[15] - The company experienced a 66.53% increase in payable taxes, totaling ¥7,935,946.99, primarily due to increased VAT payable[7] - The company reported a significant increase in accounts payable, which decreased to CNY 55,286,366.71 from CNY 63,875,802.19, a reduction of 13.5%[16] Taxation - Taxes paid decreased by 55.75% to ¥17,312,431.02 from ¥39,123,928.86 year-on-year, mainly due to tax payments from previous years made in the same period last year[8]